Seed Longevity in Desert Species and the Possibility of Forming a Persistent Soil Seed Bank von Suleiman, Majda K, Bhatt, Arvind, Jacob, Sheena, Thomas, Rini R, Sivadasan, Mini T

Volltext

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma von Choueiri, Toni K, Escudier, Bernard, Powles, Thomas, Mainwaring, Paul N, Rini, Brian I, Donskov, Frede, Hammers, Hans, Hutson, Thomas E, Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J, Bjarnason, Georg A, Géczi, Lajos, Keam, Bhumsuk, Maroto, Pablo, Heng, Daniel Y.C, Schmidinger, Manuela, Kantoff, Philip W, Borgman-Hagey, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M, Tannir, Nizar M, Motzer, Robert J

Volltext

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial von Albiges, Laurence, Tannir, Nizar M, Burotto, Mauricio, McDermott, David, Plimack, Elizabeth R, Barthélémy, Philippe, Porta, Camillo, Powles, Thomas, Donskov, Frede, George, Saby, Kollmannsberger, Christian K, Gurney, Howard, Grimm, Marc-Oliver, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I, Choueiri, Toni K, Saggi, Shruti Shally, McHenry, M Brent, Motzer, Robert J

Volltext

Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, p... von Powles, Thomas, Plimack, Elizabeth R, Soulières, Denis, Waddell, Tom, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Pouliot, Frédéric, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J, Borchiellini, Delphine, McDermott, Raymond S, Bedke, Jens, Tamada, Satoshi, Yin, Lina, Chen, Mei, Molife, L Rhoda, Atkins, Michael B, Rini, Brian I

Volltext

Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade von Motzer, Robert J., Banchereau, Romain, Hamidi, Habib, Powles, Thomas, McDermott, David, Atkins, Michael B., Escudier, Bernard, Liu, Li-Fen, Leng, Ning, Abbas, Alexander R., Fan, Jinzhen, Koeppen, Hartmut, Lin, Jennifer, Carroll, Susheela, Hashimoto, Kenji, Mariathasan, Sanjeev, Green, Marjorie, Tayama, Darren, Hegde, Priti S., Schiff, Christina, Huseni, Mahrukh A., Rini, Brian

Volltext

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma von Rini, Brian I, Plimack, Elizabeth R, Stus, Viktor, Gafanov, Rustem, Hawkins, Robert, Nosov, Dmitry, Pouliot, Frédéric, Alekseev, Boris, Soulières, Denis, Melichar, Bohuslav, Vynnychenko, Ihor, Kryzhanivska, Anna, Bondarenko, Igor, Azevedo, Sergio J, Borchiellini, Delphine, Szczylik, Cezary, Markus, Maurice, McDermott, Raymond S, Bedke, Jens, Tartas, Sophie, Chang, Yen-Hwa, Tamada, Satoshi, Shou, Qiong, Perini, Rodolfo F, Chen, Mei, Atkins, Michael B, Powles, Thomas

Volltext

First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial von Albiges, Laurence, Tannir, Nizar M., Burotto, Mauricio, McDermott, David, Plimack, Elizabeth R., Barthélémy, Philippe, Porta, Camillo, Powles, Thomas, Donskov, Frede, George, Saby, Kollmannsberger, Christian K., Gurney, Howard, Grimm, Marc-Oliver, Tomita, Yoshihiko, Castellano, Daniel, Rini, Brian I., Choueiri, Toni K., Leung, David, Saggi, Shruti Shally, Lee, Chung-Wei, McHenry, M. Brent, Motzer, Robert J.

Volltext

Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial von Regan, Meredith M., Jegede, Opeyemi A., Mantia, Charlene M., Powles, Thomas, Werner, Lillian, Motzer, Robert J., Tannir, Nizar M., Lee, Chung-Han, Tomita, Yoshihiko, Voss, Martin H., Plimack, Elizabeth R., Choueiri, Toni K., Rini, Brian, Hammers, Hans J., Escudier, Bernard, Albiges, Laurence, Huo, Stephen, Del Tejo, Viviana, Stwalley, Brian, Atkins, Michael B., McDermott, David F.

Volltext

Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma von Bedke, Jens, Rini, Brian I., Plimack, Elizabeth R., Stus, Viktor, Gafanov, Rustem, Waddell, Tom, Nosov, Dimitry, Pouliot, Frederic, Soulières, Denis, Melichar, Bohuslav, Vynnychenko, Ihor, Azevedo, Sergio J., Borchiellini, Delphine, McDermott, Raymond S., Tamada, Satoshi, Nguyen, Allison Martin, Wan, Shuyan, Perini, Rodolfo F., Rhoda Molife, L., Atkins, Michael B., Powles, Thomas

Volltext

Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Re... von Powles, Thomas, Lackner, Mark R, Oudard, Stéphane, Escudier, Bernard, Ralph, Christy, Brown, Janet E, Hawkins, Robert E, Castellano, Daniel, Rini, Brian I, Staehler, Michael D, Ravaud, Alain, Lin, Wei, O'Keeffe, Bridget, Wang, Yulei, Lu, Shan, Spoerke, Jill M, Huw, Ling-Yuh, Byrtek, Michelle, Zhu, Rui, Ware, Joseph A, Motzer, Robert J

Volltext

Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a random... von Motzer, Robert J, Escudier, Bernard, McDermott, David F, Arén Frontera, Osvaldo, Melichar, Bohuslav, Powles, Thomas, Donskov, Frede, Plimack, Elizabeth R, Barthélémy, Philippe, Hammers, Hans J, George, Saby, Grünwald, Viktor, Porta, Camillo, Neiman, Victoria, Ravaud, Alain, Choueiri, Toni K, Rini, Brian I, Salman, Pamela, Kollmannsberger, Christian K, Tykodi, Scott S, Grimm, Marc-Oliver, Gurney, Howard, Leibowitz-Amit, Raya, Geertsen, Poul F, Amin, Asim, Tomita, Yoshihiko, McHenry, M Brent, Saggi, Shruti Shally, Tannir, Nizar M

Volltext

LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma von Choueiri, Toni K, Powles, Thomas, Voss, Martin H, Plimack, Elizabeth R, Gurney, Howard, Song, Yue, Perini, Rodolfo F, Rodriguez-Lopez, Karla, Rini, Brian I

Volltext

First and Second-line Treatments in Metastatic Renal Cell Carcinoma von Barragan-Carrillo, Regina, Saad, Eddy, Saliby, Renee-Maria, Sun, Maxine, Albiges, Laurence, Bex, Axel, Heng, Daniel, Mejean, Arnaud, Motzer, Robert J., Plimack, Elizabeth R., Powles, Thomas, Rini, Brian I., Zhang, Tian, Choueiri, Toni K.

Volltext

Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes von Saliby, Renée Maria, Labaki, Chris, Jammihal, Tejas R., Xie, Wanling, Sun, Maxine, Shah, Valisha, Saad, Eddy, Kane, M. Harry, Kashima, Soki, Sadak, Katherine, El Zarif, Talal, Poduval, Deepak, Motzer, Robert J., Powles, Thomas, Rini, Brian I., Albiges, Laurence, Pal, Sumanta K., McGregor, Bradley A., McKay, Rana R., Signoretti, Sabina, Van Allen, Eliezer M., Shukla, Sachet A., Choueiri, Toni K., Braun, David A.

Volltext

Corrigendum to “Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study” [Eur Uro... von Plimack, Elizabeth R., Powles, Thomas, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Waddell, Tom, Alekseev, Boris, Pouliot, Frédéric, Melichar, Bohuslav, Soulières, Denis, Borchiellini, Delphine, McDermott, Raymond S., Vynnychenko, Ihor, Chang, Yen-Hwa, Tamada, Satoshi, Atkins, Michael B., Li, Chenxiang, Perini, Rodolfo, Molife, L. Rhoda, Bedke, Jens, Rini, Brian I.

Volltext

Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Uro... von Plimack, Elizabeth R, Powles, Thomas, Stus, Viktor, Gafanov, Rustem, Nosov, Dmitry, Waddell, Tom, Alekseev, Boris, Pouliot, Frédéric, Melichar, Bohuslav, Soulières, Denis, Borchiellini, Delphine, McDermott, Raymond S, Vynnychenko, Ihor, Chang, Yen-Hwa, Tamada, Satoshi, Atkins, Michael B, Li, Chenxiang, Perini, Rodolfo, Molife, L Rhoda, Bedke, Jens, Rini, Brian I

Volltext

Health-related quality of life (HR-QOL) measures in renal cell carcinoma (RCC): Patient-reported relevance of items of the FKSI-19, EORTC QLQ-C30, and EQ-5D von Bergerot, Cristiane Decat, Mercier, Benjamin D, Castro, Daniela V., Bergerot, Paulo Gustavo, Toms, Charlotte, Ali, Adil A, Philip, Errol James, Lages, Dr. Paulo Sergio, Mota, Augusto C. A., Hutson, Thomas E., Grünwald, Viktor, Bex, Axel, Psutka, Sarah P., Rini, Brian I., Plimack, Elizabeth R., Master, Viraj A., Albiges, Laurence, Choueiri, Toni K., Pal, Sumanta Kumar, Powles, Thomas

Volltext

Treatment-free survival and partitioned survival analysis of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib: 5-year update of C... von Mantia, Charlene M, Jegede, Opeyemi A, Plimack, Elizabeth R, Powles, Thomas, Motzer, Robert J, Tannir, Nizar M, Lee, Chung-Han, Tomita, Yoshihiko, Voss, Martin H, Choueiri, Toni K, Rini, Brian I, Hammers, Hans J, Escudier, Bernard, Albigès, Laurence, Rosenblatt, Lisa, Atkins, Michael B, Regan, Meredith M, McDermott, David F

Volltext

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma von Choueiri, Toni K., Powles, Thomas, Peltola, Katriina, de Velasco, Guillermo, Burotto, Mauricio, Suarez, Cristina, Ghatalia, Pooja, Iacovelli, Roberto, Lam, Elaine T., Verzoni, Elena, Gümüş, Mahmut, Stadler, Walter M., Kollmannsberger, Christian, Melichar, Bohuslav, Venugopal, Balaji, Gross-Goupil, Marine, Poprach, Alexandr, De Santis, Maria, Schutz, Fabio A., Park, Se Hoon, Nosov, Dmitry A., Porta, Camillo, Lee, Jae Lyun, Garcia-del-Muro, Xavier, Biscaldi, Elisa, Manneh Kopp, Ray, Oya, Mototsugu, He, Li, Wang, Aobo, Perini, Rodolfo F., Vickery, Donna, Albiges, Laurence, Rini, Brian

Volltext

Patients’ Perceptions Regarding the Relevance of Items Contained in the Functional Assessment of Cancer Therapy Kidney Symptom Index-19 von Bergerot, Cristiane Decat, Malhotra, Jasnoor, Bergerot, Paulo, Philip, Errol J, Castro, Daniela V, Hsu, JoAnn, Mota, Augusto Cesar de Andrade, Cardoso de Azeredo, Andressa, Neto, João Nunes de Matos, Hutson, Thomas, Grünwald, Viktor, Bex, Axel, Psutka, Sarah P, Rini, Brian, Plimack, Elizabeth R, Master, Viraj, Albiges, Laurence, Choueiri, Toni K, Pal, Sumanta, Powles, Thomas

Volltext